Maeda Genetics Research & Development Institute

Maeda Genetics — Research & Development Institute

A cornerstone of Sibylla’s operational continuity, Maeda Genetics now brings together scientific watch, technological advisory, medical support (prevention, treatment, MEDEVAC), and exploration/intelligence (reconnaissance, mapping, collection and brokerage of information). On deployment, our teams operate in close synergy with Orion Division — Security to open and hold corridors, and to execute extractions under fire.

HISTORY

Phase 1 — Early autonomy & the foundations of scientific intelligence.
From the very first operations, Sibylla built a fully autonomous medical capability: trained crews, relief pipelines, medbeds tailored to mission profiles, planned stocks and supply chains, MEDEVAC procedures, and continuity-of-care protocols far from UEE hubs.
In parallel, Sibylla established a Directorate of Intelligence—an advisory and archival body for civilian and partner information sources that remained within the UEE. The goal was not military action, but mission prioritization and the creation of a deployment-ready reference base: routes, phenomena, points of interest, and environmental risks.

Phase 2 — The limits of prolonged isolation & the exploratory pivot.
After years away from major centers, new vulnerabilities emerged. Medically, while trauma care and common conditions were under control, a rising average age and the lack of regular check-ups revealed chronic and age-related illnesses—sometimes forcing critical members into stasis.
On the information side, the drying up of original sources and growing operational complexity imposed a pivot: a dedicated budget for data purchase/exchange, and the deployment of non-military reconnaissance—scientific mapping, resource scouting, and anomaly inventories—to secure supply lines and anticipate risks. The resale of qualified data gradually grew to become a key economic pillar between major operational milestones.

Phase 3 — Corporate transition & structuring partnerships.
Coming out of the shadows and transforming into a corporation made it possible to address our vulnerabilities for good and to consolidate our scientific ambition. Sibylla formalized official partnerships granting access to laboratories, technology platforms, and hyper-specialized expertise that is difficult to sustain in-house. The most structuring alliance—with Maeda Genetics (originating from Maeda Pharma)—integrated and standardized its Maeda MEDEVAC Units (TT): stabilization, extraction/MEDEVAC, and transfer to higher-tier medbays—within a strictly civilian, regulated framework.
At the same time, the Directorate of Intelligence became Exploration & Scientific Intelligence within Maeda Genetics: prospecting, telemetry, spectrometry, astro-cartography, geological/biological watch, and dataset brokerage—under unified standards of quality, ethics, and traceability.

Today — Governance, ethics, and deployment.
The Research & Medical Department oversees scientific watch, ethics, qualification of emerging technologies, and their initial deployment across all divisions (industry, transport, exploration, security), ensuring consistent and lasting medical coverage—from a cargo hold to the bridges of our capital ships.
The Exploration & Scientific Intelligence branch delivers up-to-date maps, risk models, resource inventories, and phenomenon analyses for the entire corporation. Reconnaissance conducted by Maeda Genetics is exclusively scientific: no military targeting—only observation, understanding, and the delivery of actionable knowledge in support of Sibylla programs.

Regenerative Medicine

Agricultural Biotechnology

Genetic Engineering

High-Risk Research